Table 3: Phase II/III studies of chemotherapeutic agents in melanoma.

Study referenceNo. of patients eligible for analysis (followup)TNM stageTreatment armMedian followup at time of reporting (yrs)OS

Veronesi et al. 1982 [96]931II/IIIDTIC
BCG
DTIC + BCG
Obs
5NS

Lejeune et al. 1988 [97]325I, IIA, IIBDTIC
Levamisole placebo
4NS

Fisher et al. 1981 [98]181II/IIICCNU
Obs
3NS

Koops et al. 1998 [99]632II/IIIIsolated limb perfusion + hyperthermia
Obs
6.4BS

Keys: NS—not significant; S—significant; HR—hazard ratio.